(NASDAQ: AUTL) Autolus Therapeutics's forecast annual revenue growth rate of 74.7% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 98.17%, and while it is forecast to beat the US market's average forecast revenue growth rate of 25.81%.
Autolus Therapeutics's revenue in 2025 is $51,128,000.On average, 13 Wall Street analysts forecast AUTL's revenue for 2025 to be $20,725,109,967, with the lowest AUTL revenue forecast at $18,635,619,029, and the highest AUTL revenue forecast at $24,172,463,951. On average, 13 Wall Street analysts forecast AUTL's revenue for 2026 to be $39,695,271,107, with the lowest AUTL revenue forecast at $28,621,048,976, and the highest AUTL revenue forecast at $50,106,796,455.
In 2027, AUTL is forecast to generate $75,832,206,480 in revenue, with the lowest revenue forecast at $51,381,622,795 and the highest revenue forecast at $136,872,169,124.